Article
24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial.
PloS one - 1 Jan 2015
Cai Qingxian, Zhang Xiaohong, Lin Chaoshuang, Shao Xiaoqiong, Guan Yujuan, Deng Hong, Wei Min, Huang Mingshou, Ren Zefang, Lu Ling, Mei Yongyu, Xu Min, Zhu Jianyun, Shi Haiyan, Lin Guoli, Liu Ying, Hu Fengyu, Luo Qiumin, Lan Yun, Guo Fengxia, Zhao Zhixin, Gao Zhiliang
Abstract excerpt
OBJECTIVES: The optimal treatment of hepatitis C virus (HCV) genotype 6 is unclear owing to its limited geographic distribution. Because of a high predictive value of rapid virological response (RVR) for sustained virological response (SVR), we conducted an open-label randomized controlled trial to compare 24- and 48-week peginterferon/ribavirin combination therapy for patients with HCV genotype 6 in Southern...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.